Passage Bio, Inc. (PASG)

Passage Bio Statistics

Total Valuation

Passage Bio has a market cap or net worth of $27.21 million. The enterprise value is -$1.23 million.

Market Cap	27.21M
Enterprise Value	-1.23M

Important Dates

The last earnings date was Monday, November 10, 2025, before market open.

Earnings Date	Nov 10, 2025
Ex-Dividend Date	n/a

Share Statistics

Passage Bio has 3.18 million shares outstanding. The number of shares has increased by 4.39% in one year.

Current Share Class	3.18M
Shares Outstanding	3.18M
Shares Change (YoY)	+4.39%
Shares Change (QoQ)	+0.31%
Owned by Insiders (%)	0.21%
Owned by Institutions (%)	42.28%
Float	2.87M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	0.87
P/TBV Ratio	0.87
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.51, with a Debt / Equity ratio of 0.78.

Current Ratio	2.51
Quick Ratio	2.37
Debt / Equity	0.78
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -87.18% and return on invested capital (ROIC) is -38.22%.

Return on Equity (ROE)	-87.18%
Return on Assets (ROA)	-31.66%
Return on Invested Capital (ROIC)	-38.22%
Return on Capital Employed (ROCE)	-90.69%
Revenue Per Employee	n/a
Profits Per Employee	-$754,400
Employee Count	60
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -15.25% in the last 52 weeks. The beta is 1.88, so Passage Bio's price volatility has been higher than the market average.

Beta (5Y)	1.88
52-Week Price Change	-15.25%
50-Day Moving Average	7.84
200-Day Moving Average	7.70
Relative Strength Index (RSI)	55.77
Average Volume (20 Days)	42,321

Short Selling Information

The latest short interest is 82,765, so 2.60% of the outstanding shares have been sold short.

Short Interest	82,765
Short Previous Month	82,479
Short % of Shares Out	2.60%
Short % of Float	2.89%
Short Ratio (days to cover)	2.19

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-47.08M
Pretax Income	-45.26M
Net Income	-45.26M
EBITDA	-45.81M
EBIT	-47.08M
Earnings Per Share (EPS)	-$14.57

Balance Sheet

The company has $52.77 million in cash and $24.34 million in debt, giving a net cash position of $28.44 million or $8.95 per share.

Cash & Cash Equivalents	52.77M
Total Debt	24.34M
Net Cash	28.44M
Net Cash Per Share	$8.95
Equity (Book Value)	31.12M
Book Value Per Share	9.79
Working Capital	33.49M

Cash Flow

In the last 12 months, operating cash flow was -$33.47 million and capital expenditures -$14,000, giving a free cash flow of -$33.49 million.

Operating Cash Flow	-33.47M
Capital Expenditures	-14,000
Free Cash Flow	-33.49M
FCF Per Share	-$10.54

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Passage Bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-4.39%
Shareholder Yield	-4.39%
Earnings Yield	-166.35%
FCF Yield	-123.07%

Analyst Forecast

The average price target for Passage Bio is $34.50, which is 303.04% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$34.50
Price Target Difference	303.04%
Analyst Consensus	Strong Buy
Analyst Count	4
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on July 14, 2025. It was a reverse split with a ratio of 1:20.

Last Split Date	Jul 14, 2025
Split Type	Reverse
Split Ratio	1:20

Scores

Altman Z-Score	n/a
Piotroski F-Score	1